Tirofiban
Brand: Aggrastat (US/EU) / Aggril (IN) / Tirof (BD)
Antiplatelet
GP IIb/IIIa inhibitor (IV, small-molecule)
Pharmacokinetics
| Half-life | 2 hours |
| Tmax | 0 h |
| Protein Binding | 65 % |
| Volume of Distribution | 0.15 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Short-acting GP IIb/IIIa inhibitor; dose adjustment required in renal impairment; used for PCI and ACS. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Bleeding, thrombocytopenia, hypotension
Contraindications:
Active major bleeding, history of hemorrhagic stroke, severe renal impairment unless dose adjusted
Precautions:
Monitor renal function; adjust dose if CrCl <30 ml/min; avoid neuraxial anesthesia timing overlap